Search clinical trials for: Alpha linolenic acid/ALA

Total 29257 results

NRG Oncology
National Cancer Institute (NCI)

Recruiting

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Prostate Adenocarcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.

Active, not recruiting

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Malignant Solid Neoplasm | Soft Tissue Sarcoma | Recurrent Ovarian Carcinoma | Triple Negative Breast Cancer | Recurrent Osteosarcoma | Refractory Osteosarcoma | Bone Sarcoma | Giant Cell Tumor of Bone | Ovarian Carcinosarcoma | Platinum-Resistant Ovarian Carcinoma | Dedifferentiated Chondrosarcoma | Malignancy... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Terminated

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL)

Acute Adult T-Cell Leukemia/Lymphoma | Adult T-Cell Leukemia/Lymphoma | Chronic Adult T-Cell Leukemia/Lymphoma | HTLV-1 Infection

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent Burkitt Lymphoma | AIDS-Related Burkitt Lymphoma | Atypical Burkitt/Burkitt-Like Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma

United States
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; North Central...

Active, not recruiting

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Breast Adenocarcinoma

United States, Peru, South Africa
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7

United States
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Canadian Cancer Trials Group; Southwest Oncology... and other collaborators

Completed

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

HER2 Positive Breast Carcinoma | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States, Canada, Peru, South Africa
National Cancer Institute (NCI)

Recruiting

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

United States, Puerto Rico, Canada
Mayo Clinic

Recruiting

Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study

Glioblastoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed B-Cell Non-Hodgkin Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma | Refractory Primary Mediastinal (Thymic)... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

Richter Syndrome | Recurrent Transformed Chronic Lymphocytic Leukemia | Refractory Transformed Chronic Lymphocytic Leukemia

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score

Prostate Adenocarcinoma

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

Lymphoma | Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Lymphocytic Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

Metastatic Malignant Neoplasm in the Liver | Advanced Malignant Neoplasm | Refractory Malignant Neoplasm | Colorectal Carcinoma Metastatic in the Liver

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Ovarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditions

United States, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Suspended

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

Medulloblastoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Bladder Urothelial Carcinoma | Stage IIIA Bladder Cancer AJCC v8 | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes (The INSPIRE Study)

Stage III Bladder Cancer AJCC v8 | Bladder Urothelial Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Refractory Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Lymphoma | Clonal Cytopenia of Undetermined Significance | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

United States
National Cancer Institute (NCI)

Recruiting

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

AL Amyloidosis

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Recurrent Hodgkin Lymphoma | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Aplastic Anemia | Recurrent Non-Hodgkin... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

Stage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Stage I Childhood Hodgkin Lymphoma | Stage II Childhood Hodgkin Lymphoma | Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma | Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma | Childhood Mixed Cellularity... and other conditions

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland, Israel
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Alveolar Rhabdomyosarcoma | Embryonal Rhabdomyosarcoma | Botryoid-Type Embryonal Rhabdomyosarcoma | Spindle Cell Rhabdomyosarcoma | Spindle Cell/Sclerosing Rhabdomyosarcoma | Metastatic Embryonal Rhabdomyosarcoma | Metastatic Rhabdomyosarcoma | Solid Alveolar Rhabdomyosarcoma

United States, Canada, Australia, Puerto Rico, Saudi Arabia
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Recruiting

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Stage IV Nasopharyngeal Carcinoma AJCC v8 | Stage II Nasopharyngeal Carcinoma AJCC v8 | Stage III Nasopharyngeal Carcinoma AJCC v8

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Intraductal Papillary-Mucinous Neoplasm | Stage I Pancreatic Cancer AJCC v6 and v7 | Stage II Pancreatic Cancer AJCC v6 and v7

United States, Canada, Israel, Belgium
National Cancer Institute (NCI)

Active, not recruiting

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Ann Arbor Stage IIIB Hodgkin Lymphoma | Ann Arbor Stage IVA Hodgkin Lymphoma | Ann Arbor Stage IVB Hodgkin Lymphoma | Classic Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma | Childhood Hodgkin Lymphoma

United States, Canada, Puerto Rico
University of Nebraska
National Cancer Institute (NCI)

Completed

Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Negative | Recurrent Anaplastic Large Cell Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type

United States, Saudi Arabia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | CD19 Positive

United States
National Cancer Institute (NCI)

Recruiting

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Recurrent Adult Lymphoblastic Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma | Breast Inflammatory Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain

United States
University of Southern California
National Cancer Institute (NCI)

Not yet recruiting

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Triple Negative Breast Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Double-Expressor Lymphoma | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise... and other conditions

United States
Children's Oncology Group

Not yet recruiting

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Stage I Kidney Wilms Tumor | Stage II Kidney Wilms Tumor | Stage III Kidney Wilms Tumor | Stage IV Kidney Wilms Tumor
National Cancer Institute (NCI)

Active, not recruiting

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma | Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma | Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Ann Arbor Stage IV... and other conditions

United States, Canada, Puerto Rico
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade... and other conditions

United States
Fred Hutchinson Cancer Center

Active, not recruiting

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Myasthenia Gravis | Neuromyelitis Optica | Autoimmune Disease | Chronic Inflammatory Demyelinating Polyneuropathy | Lambert Eaton Myasthenic Syndrome | Cerebellar Degeneration | Stiff Person Syndrome | Opsoclonus Myoclonus Syndrome | Neurologic Autoimmune Disease | Autologous Transplant Autoimmune | Multiple... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study

Metastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v7

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Unresectable Colorectal Carcinoma

United States
QuantumLeap Healthcare Collaborative

Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)

Breast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer

United States
National Cancer Institute (NCI)

Recruiting

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States

Search clinical trials for: Alpha linolenic acid/ALA

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations